|
Multiple Myeloma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Subsequently, current literatures are presented to reveal the molecular mechanisms of PARP14 as a novel drug target for cancers (e.g., diffuse large B-cell lymphoma, multiple myeloma, prostate cancer, and hepatocellular carcinoma) and allergic inflammatory.
|
30890936 |
2019 |
|
Multiple Myeloma
|
0.030 |
Biomarker
|
disease |
BEFREE |
PARP14 is involved in normal immune function through the IL-4 signaling pathway and is a prosurvival factor in multiple myeloma and hepatocellular carcinoma.
|
30247868 |
2018 |
|
Multiple Myeloma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our findings reveal a novel regulatory pathway in myeloma cells through which JNK2 signals cell survival via PARP14, and identify PARP14 as a potential therapeutic target in myeloma.
|
23045269 |
2013 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
PARP-14 has recently appeared to be involved in the transduction pathway mediated by JNKs (c Jun N terminal Kinases), among which JNK2 promotes cancer cell survival.
|
31130919 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
PARP-14 has recently appeared to be involved in the transduction pathway mediated by JNKs (c Jun N terminal Kinases), among which JNK2 promotes cancer cell survival.
|
31130919 |
2019 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Subsequently, current literatures are presented to reveal the molecular mechanisms of PARP14 as a novel drug target for cancers (e.g., diffuse large B-cell lymphoma, multiple myeloma, prostate cancer, and hepatocellular carcinoma) and allergic inflammatory.
|
30890936 |
2019 |
|
Asthma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Much of the data resulting from different laboratories support the role of poly(ADP-ribose) polymerase (PARP) 1 and PARP14 activation in asthma.
|
29483769 |
2018 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
PARP14 is involved in normal immune function through the IL-4 signaling pathway and is a prosurvival factor in multiple myeloma and hepatocellular carcinoma.
|
30247868 |
2018 |
|
Asthma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Furthermore, PARP-14 seems to play a crucial role in asthma.
|
28974953 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
PARP14, the original member of the PARP family, has been reported to be associated with the development of inflammatory diseases and various cancer types, making it a potential therapeutic target.
|
28315326 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
PARP14, the original member of the PARP family, has been reported to be associated with the development of inflammatory diseases and various cancer types, making it a potential therapeutic target.
|
28315326 |
2017 |
|
Glucagonoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we provide evidence on the activation of a survival pathway, mediated by PARP-14, in pancreatic α cells, following treatment of αTC1.6 glucagonoma and βTC1 insulinoma cell lines with a cytokine cocktail: interleukin 1 beta (IL-1β), interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α).
|
31130919 |
2019 |
|
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Therefore, PARP14 has been considered a fascinating target for treatment of tumors and allergic inflammation.
|
30890936 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Subsequently, current literatures are presented to reveal the molecular mechanisms of PARP14 as a novel drug target for cancers (e.g., diffuse large B-cell lymphoma, multiple myeloma, prostate cancer, and hepatocellular carcinoma) and allergic inflammatory.
|
30890936 |
2019 |
|
Pancreatic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
And inhibition of NF-κB signal could significantly reverse PARP14-overexpression triggered PC carcinogenesis.
|
30968979 |
2019 |
|
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
And inhibition of NF-κB signal could significantly reverse PARP14-overexpression triggered PC carcinogenesis.
|
30968979 |
2019 |
|
Carcinogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
And inhibition of NF-κB signal could significantly reverse PARP14-overexpression triggered PC carcinogenesis.
|
30968979 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Subsequently, current literatures are presented to reveal the molecular mechanisms of PARP14 as a novel drug target for cancers (e.g., diffuse large B-cell lymphoma, multiple myeloma, prostate cancer, and hepatocellular carcinoma) and allergic inflammatory.
|
30890936 |
2019 |
|
Dermatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
To further our understanding of PARP14 in allergic disease, we studied the function of PARP14 in allergic inflammation of skin using mice that express constitutively active Stat6 in T cells (Stat6VT) and develop spontaneous inflammation of the skin.
|
28653395 |
2017 |
|
Dermatologic disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Poly-ADP ribose polymerase-14 limits severity of allergic skin disease.
|
28653395 |
2017 |
|
Unipolar Depression
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A Novel Relationship for Schizophrenia, Bipolar, and Major Depressive Disorder. Part 8: a Hint from Chromosome 8 High Density Association Screen.
|
27660274 |
2017 |
|
airway disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Poly-ADP ribose polymerase-14 (PARP14 or ARTD8) was initially identified as a transcriptional co-activator for signal transducer and activator of transcription 6 (Stat6), where the presence of interleukin-4 (IL-4) and activated Stat6 induces the enzymatic activity of PARP14 that promotes T helper type 2 differentiation and allergic airway disease.
|
28653395 |
2017 |
|
Major Depressive Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A Novel Relationship for Schizophrenia, Bipolar, and Major Depressive Disorder. Part 8: a Hint from Chromosome 8 High Density Association Screen.
|
27660274 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells.
|
24886089 |
2014 |
|
Metastasis from malignant tumor of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells.
|
24886089 |
2014 |